Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - PowerPoint PPT Presentation

Loading...

PPT – Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 PowerPoint presentation | free to download - id: 800b0a-NjE0M



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Pancreatic Cancer Therapeutics in Major Developed Markets to 2021

Description:

Research Beam added a report on “Pancreatic Cancer Therapeutics in Major Developed Markets to 2021” Enquiry about report: – PowerPoint PPT presentation

Number of Views:19

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Pancreatic Cancer Therapeutics in Major Developed Markets to 2021


1
Pancreatic Cancer Therapeutics in Major Developed
Markets to 2021 - Strong Late Stage Pipeline
Holds Promise for Increasingly Diverse Market
Landscape
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
TELEPHONE 1 (503) 894-6022 E-MAIL
sales_at_researchbeam.com
Published on Oct 2014
2


Report Overview
  • Scope
  • Global revenues for the PC market are forecast to
    rise at a moderate CAGR of 7.6 from 1.746bn in
    2014 to 2.92bn in 2021.
  • - What factors are driving the market growth?
  • - How can the factors limiting growth be
    overcome in the future?
  • The variation in mechanism of action has shifted
    away from the traditional chemotherapies, which
    dominate the marketed products, but account for
    only 7 of the pipeline. 44 of the pipeline are
    drugs inhibiting signal transduction.
  • - What are the dynamics of the remaining 49 of
    the pipeline?
  • - How does this reflect the need for novel
    targeted therapies?
  • Key mechanisms of action across the pipeline
    include cancer immunotherapies against IAP repeat
    containing proteins, whole cell vaccines and
    targeted therapies against the PI3K/Akt/mTOR
    pathway.
  • - What is the scientific rationale behind these
    targets?
  • Several drugs are expected to be approved during
    the forecast period TH-302, ruxolitinib
    phosphate, HyperAcute Pancreas, G17DT and
    clivatuzumab tetraxetan. However, their sales
    will be limited by their expected high costs.
  • Read More At http//www.researchbeam.com/pancreat
    ic-cancer-therapeutics-in-major-developed-to-2021-
    strong-late-stage-pipeline-holds-promise-for-incre
    asingly-diverse-landscape-market

3


Table of Content
1 Table of Contents 6 1.1 List of Tables 8 1.2
List of Figures 9 2 Introduction 11 2.1 Disease
Introduction 11 2.2 Epidemiology 11 3 Commercial
and Clinical Prospects of Marketed Products
24 3.1 Approved Products 24 3.2 Off-Label
Products 30 4 Pipeline for Pancreatic Cancer
Therapeutics 36 4.1 Overview by Phase and
Molecule Type 37 4.2 Overview by Molecular Target
38 5 Market Forecast to 2021 72 5.1 Global
Market 73 5.2 North America 74
4


Table of Content
6 Drivers and Barriers 87 6.1 Drivers 87 6.2
Barriers 89 7 Strategic Consolidations 91 7.1
Major Co-Development Deals 91 7.2 Major Licensing
Deals 95 8 Appendix 100 8.1 All Pipeline Drugs
by Phase 100 8.2 Market Forecasts to 2020
114 Enquire At http//www.researchbeam.com/pa
ncreatic-cancer-therapeutics-in-major-developed-to
-2021-strong-late-stage-pipeline-holds-promise-for
-increasingly-diverse-landscape-market/enquire-abo
ut-report
5



FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/pancreatic-cancer-ther
apeutics-in-major-developed-to-2021-strong-late-st
age-pipeline-holds-promise-for-increasingly-divers
e-landscape-market
Stay With Us
5933 NE Win Sivers Drive, 205, Portland, OR
97220 United States
TELEPHONE 1 (800) 910-6452 DIRECT 1 (503)
894-6022 E-MAIL sales_at_researchbeam.com
About PowerShow.com